All lobbying filings

ARNOLD & PORTER KAYE SCHOLER LLP

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company.

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Income

$70,000.00

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Lobbyists on this filing 1

MARK EPLEY New on this filing

Previously held: Sr Advisor/GC, Office of Speaker (2015-19); Comm GC/Staff Dir, Oversight Sub, House Ways & Means (2012-15); Staff Dir, Oversight Sub, House Fin Services (2011-12); Sr Coun, DOJ Dep AG (2006-08); GC & Counsel, Mil Per Sub, House Armed Services (2005)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 4818
Treat and Reduce Obesity Act of 2023
S 2407
Treat and Reduce Obesity Act of 2023

Lobbying activity 4

Pharmacy

Issues related to pharmacy benefit managers (PBMs). Issues related to the 340B Program. Issues related to general compounding.

Health Issues

Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.

Medicare/Medicaid

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).

Consumer Issues/Safety/Products

Issues related to general compounding.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.